Haloperidol clinical trials results
Delirium is an important problem in critical care. Its prevalence often reaches 75% in intensive care patients. Its occurrence is associated with numerous complications and deleterious consequences such as death, longer stay, higher cost, and long-term cognitive impairment. Delirium treatment entails correcting its underlying causes and usually initiating a pharmacological intervention with an antipsychotic. Typical antipsychotics, particularly haloperidol, are commonly used to treat delirium although few placebo-controlled trials of pharmacological treatments for delirium have been conducted. Furthermore, appropriate doses for delirium treatment have yet to be established. In critical care, two pilot studies provided the first randomized, placebo-controlled evidence for the pharmacologic treatment of ICU delirium. One found that neither haloperidol nor ziprasidone significantly reduced the incidence or duration of delirium compared with placebo whereas the other one found that quetiapine added to as-needed haloperidol resulted in faster delirium resolution.
The goal of this study is to determine the effectiveness of antipsychotics in regular dosage regimen (quetiapine group and haloperidol group) compared to as-needed haloperidol (placebo group) in the pharmacological treatment of delirium. We will conduct a three-arm randomized controlled trial to achieve this goal.
Materials and Methods:
During one year, 45 delirious patients from three intensive care units will be recruited and randomized into one of three groups. Randomization will be performed in blocks of 9 by the pharmacy department, using a random numbers table.
Patients will be continuously screened for delirium using the Intensive Care Delirium Screening Checklist (ICDSC) as part of routine care. A positive screening score (≥4) will warrant confirmation of delirium diagnosis by the treating physician. Treatment will begin according to randomization group, provided that informed consent has been obtained. Delirium status will be monitored during the episode using the Nursing Delirium Screening Scale (Nu-DESC). When the Nu-DESC monitoring will become negative for delirium (total score below 2), the resolution of the episode will be confirmed by the treating physician. A clinical evaluation by a psychiatrist will be performed within 24-48 hours of each of the two evaluations made by the treating physician (beginning and end of the delirium episode).
Prost-P10x. Professional Strength Natural Prostate Supplement. Available without a Prescription. Doctor Formulated by Leading Naturopathic Urologist. Graminex Flower Pollen Extract, Quercetin, Meriva® Curcumin, DIM, Beta-sitosterol, Saw Palmetto + 6 Additional Extra Strength Natural Ingredients For Maximum Prostate Health. Therapeutic Dose (3320+mg/1000 IU), Professional Grade, 100% Natural, Maximum Strength for Men Looking for Results. Proudly Developed in the USA.
Health and Beauty (Douglas Laboratories)
BMC Medical Research Methodology at the 35th Annual Conference of the .. — BMC Pediatrics
The conference will focus on issues such as design and analysis of clinical trials, methods in biostatistics and development of clinical prediction models.
Curcumin Longvida Powder by Nutrivene (30 grams)
Health and Beauty (Nutrivene)
Pure Encapsulations - CurcumaSorb - 180ct
Health and Beauty (Pure Encapsulations)
Thorne Research, Meriva-500 (120 Caps) Pack of 2
Health and Beauty (Thorne Research)
Gaia Herbs Turmeric Supreme Pain P.M, 60 Count
Health and Beauty (Gaia Herbs)
What were the clinical results of the tuskegee study?
The results of the Tuskegee study are actually quite broad and too in depth to put into the text message character limit.